News
25 September 2026
Consistently Maintaining Halal Standards, Dexa Group Wins IHYA 2026
TANGERANG — PT Ferron Par Pharmaceuticals, a member of Dexa Group, has won the 2026 Indonesia Halal Industry Award (IHYA) from the Ministry of Industry of the Republic of Indonesia in the Large Industrial Enterprise Category, Subcategory of Best Pharmaceuticals and Traditional Medicines. This award recognizes Dexa Group’s consistency in…
24 September 2026
From Medications to Facilities, Ferron Strengthens Support for Cancer Patients
JAKARTA — Indonesia recorded 474,083 new cases and 283,299 deaths due to cancer, according to 2024 Global Cancer Observatory (GLOBOCAN) data. This situation underscores the critical role of Ferron Par Pharmaceuticals in expanding its support for cancer patients—from delivering access to medications to strengthening chemotherapy support facilities through the provision…
23 September 2026
Dharma Dexa Implements “Deal with Care” for Disaster-Affected Communities in 2026
JAKARTA — Amid a series of natural disasters impacting various regions across Indonesia throughout 2026, Dexa Group, through its Corporate Social Initiative Dharma Dexa, continues to strengthen its commitment to safeguarding health and inspiring hope for affected communities. This step marks part of Dexa Group's 57th-anniversary spirit to extend meaningful…
21 July 2026
Strengthening the Government’s Preventive Health Efforts, Sustainable Health Program Reaches More Than 16,500 People
JAKARTA – More than 16,500 people across Indonesia have participated in the Cek Kesehatan Segitiga, a free health screening program organized by Dexa Medica through Dharma Dexa since 2024. Beyond providing blood pressure, blood glucose, and cholesterol screenings, the program, now conducted at 22 locations, also integrates health education, medical…
14 July 2026
Supporting the National Health Program, Cek Segitiga Serves More Than 15,000 People
Surabaya – Through Dharma Dexa, Dexa Medica continues to implement Cek Segitiga, a free community health screening program that supports the Indonesian government’s efforts to strengthen the early detection of non-communicable diseases (NCDs). Since its launch in 2024, the program has reached more than 15,000 people through blood pressure, blood…
8 July 2026
OGB Merah at HISFARSI 2026: Reflecting Quality, Strengthening Trust
The quality of generic medicines can be demonstrated both through the production process and through the trust placed in them by healthcare professionals who use them in their practice. Building on this commitment, PT Dexa Medica presented "OGB Merah, A Reflection of Quality Generic Medicine" at the HISFARSI 2026 National…
19 June 2026
CorComm Dream Team 2026: Beyond Words, Toward Real Impact
Corporate reputation stems from consistent effort. It is built upon the ability to assess situations, deliver information transparently, maintain trust, and ensure that every message is grounded in accountability. This is the exact principle upheld by Dexa Group’s Corporate Communications department in supporting the company’s journey as a growing Indonesian…
12 June 2026
Dexa Medica Molecular Pharmacologist Prof. Raymond Tjandrawinata Ranked Among the Top 5% of Scientists Worldwide
JAKARTA — Prof. Raymond Tjandrawinata, Molecular Pharmacologist at PT Dexa Medica, has been ranked among the Top 5% of Scientists Globally by the SciRank Global Database. The recognition follows an extensive evaluation of more than 8 million researchers, 20 million scientific publications, and academic data from over 150 countries. "I…
9 June 2026
From Preventive Action to Meaningful Impact: Dexa Group Receives CSR Award 2026
Dexa Group's commitment to expanding healthcare access has once again been recognized. The company was honored with The Best Corporate Social Responsibility Award 2026 for Strengthening Social Solidarity and Healthcare Access Through Preventive Actions at the Indonesia Corporate Social and Environmental Responsibility Awards 2026, organized by Warta Ekonomi. The award…
4 June 2026
Head of Indonesia’s FDA Launches Ferron Par Pharmaceuticals’ 150th Export Container to Europe, Demonstrating the Global Competitiveness of Indonesia’s Pharmaceutical Industry
Eighteen years ago, PT Ferron Par Pharmaceuticals shipped its first pharmaceutical products from Indonesia to the European market. On Thursday (June 4, 2026), the company marked another significant milestone with the official dispatch of its 150th export container from Ferron’s manufacturing facility in Cikarang, West Java. The ceremony was officiated…